

Viola W Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6851781/publications.pdf>

Version: 2024-02-01

57
papers

4,324
citations

172386

29
h-index

161767

54
g-index

58
all docs

58
docs citations

58
times ranked

4113
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 411-422.	0.5	70
2	INSIGHT 2: a phase II study of tepotinib plus osimertinib in <i>MET</i> -amplified NSCLC and first-line osimertinib resistance. <i>Future Oncology</i> , 2022, 18, 1039-1054.	1.1	30
3	Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. <i>Cancer Discovery</i> , 2022, 12, 1676-1689.	7.7	30
4	Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 740-763.	0.5	115
5	A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100116.	0.6	12
6	Identification of Novel CDH1-NRG2± and F11R-NRG2± Fusions in NSCLC Plus Additional Novel NRG2± Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100132.	0.6	7
7	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	7.7	154
8	Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909.	3.2	62
9	Acquired Resistance to KRAS ^{G12C} Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2382-2393.	13.9	482
10	Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 61-65.	1.3	6
11	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 959-969.	5.1	222
12	Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 157, 147-155.	0.9	30
13	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100187.	0.6	11
14	Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib. <i>Journal of Thoracic Oncology</i> , 2021, 16, e51-e54.	0.5	16
15	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. <i>Lung Cancer</i> , 2021, 158, 126-136.	0.9	53
16	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. <i>Lancet Diabetes and Endocrinology</i> , the, 2021, 9, 491-501.	5.5	192
17	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. <i>Journal of Clinical Oncology</i> , 2021, 39, 2791-2802.	0.8	32
18	Will the clinical development of 4th-generation double mutant active-ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. <i>Translational Oncology</i> , 2021, 14, 101191.	1.7	24

#	ARTICLE	IF	CITATIONS
19	Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1778-1781.	0.5	0
20	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist</i> , 2020, 25, e39-e47.	1.9	13
21	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265.	0.5	53
22	Catalog of 5â€² fusion partners in RET+ NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100037.	0.6	17
23	The Next Target for NSCLC: Let It Be â€œRETâ€. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1803-1805.	0.5	1
24	Efficacy of Selpercatinib in <i>i>RET</i>-Altered Thyroid Cancers. <i>New England Journal of Medicine</i>, 2020, 383, 825-835.</i>	13.9	454
25	Multimodal Bronchoscopic Treatment of Unresectable Tracheal Adenoid Cystic Carcinoma. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2020, 27, e17-e19.	0.8	1
26	An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitorâ€œRefractory ALK-Positive or ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1484-1496.	0.5	43
27	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1611-1623.	0.5	43
28	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. <i>Lung Cancer</i> , 2020, 145, 186-194.	0.9	68
29	U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 4785-4794.	3.2	63
30	Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, e124-e127.	0.5	28
31	<p>Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 13-18.	1.3	6
32	Catalog of 5â€²™ Fusion Partners in ALK-positive NSCLC Circa 2020. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100015.	0.6	62
33	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 2521-2534.	1.3	15
34	Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Trends in Cancer</i> , 2019, 5, 677-692.	3.8	43
35	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	0.9	85
36	<p>Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 21-26.	1.3	22

#	ARTICLE	IF	CITATIONS
37	CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. Lung Cancer, 2019, 130, 201-207.	0.9	35
38	Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK-Positive Non-Small-Cell Lung Cancer: Histologic Analysis. Clinical Lung Cancer, 2019, 20, e77-e80.	1.1	9
39	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. JCO Precision Oncology, 2018, 2018, 1-12.	1.5	112
40	Liquid Biopsy to Identify Actionable Genomic Alterations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 978-997.	1.8	54
41	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1199-1206.	0.8	246
42	Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation. Lung Cancer: Targets and Therapy, 2018, Volume 9, 111-116.	1.3	6
43	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discovery, 2018, 8, 1529-1539.	7.7	342
44	Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent-Front Mutations. Cancer Discovery, 2018, 8, 1227-1236.	7.7	321
45	Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR- β N848A mutation. Lung Cancer, 2018, 124, 86-89.	0.9	0
46	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. Journal of Thoracic Oncology, 2018, 13, 1530-1538.	0.5	62
47	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1312-1323.	0.5	103
48	Pacific Rim redux: lorlatinib, the ultimate Jaeger?. Annals of Translational Medicine, 2018, 6, S40-S40.	0.7	1
49	Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 509-514.	1.0	10
50	A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary) Tj ETQq0 0 0 rgBT/Overlock, 10 Tf 50 2	0.6	9
51	Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer, 2017, 110, 32-34.	0.9	16
52	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer, 2017, 108, 228-231.	0.9	125
53	Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?. Lung Cancer, 2017, 106, 110-114.	0.9	64
54	MET ex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure?. Journal of Thoracic Oncology, 2017, 12, 1180-1182.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2017, 12, 137-140.	0.5	102
56	The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. <i>Lung Cancer</i> , 2017, 103, 27-37.	0.9	136
57	ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 660-664.	1.3	0